The objective of this observational study is to determine if the safety profile of niraparib in real-world patient populations differs from the clinical trial findings. 

The need to monitor and manage adverse events means that patients must visit their health care providers more frequently. Real-world evidence may assist decision-making by supplementing the clinical trial data.

Read our full study report on the CDA Website by clicking here.